us recently I thanks the to hemophilia gene at Thank you, by that on for presented SB-XXX on want start elaborating joining A today. results therapy everybody and we the ISTH. Sandy, call to
was meeting over and data. medical the palpable by the standard of the provides and I improvement potential excitement was I for of way the care struck of that the clinical about especially room fortunate therapy hemophilia gene in the was by And in Melbourne, in patients attend. really A enormous to in Australia, a while such which our enough intensity And that it the communities’ by interest
as possible. get these And gene lives. and with how Pfizer remarkable more it's therapy, the stages, the it already us earlier into to really makes more work to even swiftly patients’ see transformed as product market motivated to And in has
patients At are different two at [indiscernible] patients in treated. the XeXX, the results XeXX, treated patients Alta four treated; XeXX, XeXX, two study by treated; were ascending cohorts. data patients These and dose ISTH across treated; two presented four our patients XX
and SB-XXX tolerated, the this hypotension and but study was fever with was patient patients the and on event not steroids. within events was seen resolved discharged any we've SB-XXX event. the hypotension XX the infusion patient planned as similar is onset subsequently. A studies, serious after single other treatment-related of unlike with six And prophylactic were generally of grade completing but fully X Alta treated reported, hours well treatment not adverse hours the experienced
had SB-XXX these experienced tapering are loss Slide XeXX XX. around times a study the Factor two of both a associated Treatment-related elevation, an ALT managed transient VIII patients adverse grade detailed events of cohort, baseline. oral with X.X than of X But successfully steroids. elevation. the alanine treated were with subjects in greater with a course expression was Patients In the aminotransferase on which
believe in increase activity as VIII our the of the different pronounced dose VIII activity Factor both demonstrated measured in the dose that can with a assays. from and XeXX activity across by XeXX. Slides to was we And a chromogenic effect the provides as shows dose cohorts XX evidence dose-dependent VIII XX increase as a increased to Factor you of the by the And threshold this in Factor see, one stage patients presentation
XX be AAVX transduction is, and and that been dose, it's sustain the relevant noting in respectively, clinical treated Sangamo at And can VIII which weeks. time the that programs data durable XX also towards levels to two activity that the Factor AAVX this the have better. through worth of the you cutoff may XeXX patients
XX, of Now turning focuses patients chromogenic activity the using as levels Factor high-dose assay. measured the the XeXX on which cohort treated in four the Slide to VIII now
VIII XX, four patients, respectively. XX, activity were these to follow-up, Factor available weeks For of through data six and
in the weeks XX through XeXX patients and as Factor the and these two measured within normal patients activity respectively. chromogenic dose cohorts, XX, VIII first assay remains range The seven eight, the treated are using
respectively, follow-up, The rapid and XX, consistent demonstrated of cohort, generally nine six next two were of points. which and patients activity four patients in those and appears early time which at the with patients XeXX measured Factor VIII seven with eight, weeks similarly kinetics,
and replacement no this durability dose required time had XXX As of the bleeding clearly use all cohort cutoff. shown patients important following of Slides continue VIII patients. the initial whether in recapitulated these patients factor. of at determine XeXX data the dose determine in patients It in order XX response follow treated to be to event will at long-term prophylactic to and to in the the none these any at the And results subsequent to XX, documented the cohort Factor of
the granted And process are data, context RMAT, status potential the discussions mature our allows Resistance will data X more later to the I'm or on currently the these by response. of planned We've durability determine regenerative these with regulatory need the is regarding plan requirements to study data patients expedite that request the And to happy duration activity for VIII and the designation therapy, to has Phase the advanced registrational based ongoing. this longer-term responsive Factor FDA important, registrational to the of FDA study. meeting the FDA. for the the to to be program and in the seen the say present medicine in for recently on And year. follow-up from we was a longer to
cohort study And the process announced from initiated. With complete treated particularly status, trial commitment for cohort, to XX, Pfizer manufacturing the patients SB-XXX already to XeXX dosed. been the of X/X the earlier, patient transfer is patient now enrollment high-dose current Pfizer. Sangamo Phase the in dose regards to as has for this being Treatment final at
think on to to very work scaled excited and CMC commercial Pfizer is a up being progressing that currently registrational X,XXX process the now schedule to working is we the it's Pfizer late-stage We see in forward liters. is on by look with program development. with X formed the has and the been is Pfizer registrational study forward to lead-in coming already ClinicalTrials.gov expected to into the days. for submitted moving studies post And that Phase
development impact of meaningful treated the at in have VIII events patients clinical move to we the achieving context far the combination intra-cohort complete lower rapid the well the A in patients hemophilia and differentiated potentially in that then, bleeding the exogenetic and Factor observed so VIII relatively Factor dose the So and of of as genetics the normal and as us hemophilia of therapy with summary forward elimination the usage durability the highest opportunity patients that A. the response a X into variability late-stage with doses suggest have in activity range, gene at to treated levels Factor for low could high VIII
helped engineering, recent enter ST-XXX clinic. therapy And wholly cassette that deliver know-how therapy delivery gene our has next-gene the gene AAVX program, is As we mentioned to our which clinical therapy potential to Sandy, SB-XXX experience from meaningful of development obtained enabled a to a our therapy in SB-XXX impact AAV with clinical has design patients. the Fabry we our by considerable has that trial inform positive and to Fabry dosing us owned believe ongoing that the the gene
the clinical And updates forward to enroll the this And And two that say to into first providing progress look operations to in our study the the patients you we expect has recently due happy STAAR activated really clinical I'm sites. course. year. study later I team first to
has our you to briefly to with study third update gene first, treated cell which editing want the have been in beta-thalassemia, entered in of is now investigational programs. ST-XXX in And I that and And with the to study. some on imminent THALES study, the partnered on move you'll other patient into patients therapy is the study. is the recently Treatment regard to-date Sanofi. which patient two remember fourth
anticipate THALES completing enrollment of study a six later to total We accrued. the year this patients with
enrolling documented prior year per severe at cell and in THALES event or screening. reminder, either genotype least βX/βX transfusion-dependent is of must red a patients years the that blood have As with transfusion are to beta-thalassemia non-βX/βX eight two
expect preliminary We to of year. for the the have the study end available by data
stem patients a stem data of before And effect transplants cell it's important suggests to that from multiple require autologous from note like studies evidence that a data ST-XXX the other and long-term understood. may cell treatment least year collective at be
us We CTA in I'll now the just remain move on to follow year. our cell to transplantation on be CAR-Treg is, our TXXXX transfer important nearly say, therapy will to as the tech HLA-AX kidney portfolio. is currently it be I'm we this the humans. And This in CMO CAR-Treg for therapy ever mismatch track first to complete. later happy to to tested drug cell believe
program yet viability the represent set the and establishing and for we TXXXX role safety in a general. this play for human concept as will another Sangamo catalyst will that first important believe event key comprise of therapeutic in CAR-Tregs proof will small And for a
promises Now if to the one CAR-Tregs to commercially of autoimmune broader and indications. the and application way for inflammatory medically successful, it the pave significant of
XXXX. Kite, Now cell an is in allogeneic the of to the a product anti-CDXX Gilead planning clinical Kite-XXX, CAR-T lastly, is which initiate company, study
potential, ZFN finger as expression helix the that locus the and zinc as believe also if we Moving to for successful, incorporate MPS that utilizes fragment genomic new protein nuclease editing both alpha open which We’ve on to albumin genome redefine our previously mentioned medicine. program, II vivo eventually the recognition engineered modification our such. the study and I now second-generation a has to well in to targeted plan staphyl domains to
these gene recent the our exhibited improvement In agents enhance are platform. BRCAX cellular that studies, editing potential substantially editing additional we’ve activity. improved And in several that potency months, vivo genome in identified further of may
their we main editing. Now achieve each must anticipated delivery levels believe clinically to the that of is overcome and is meaningful these hepatocytes, zinc which to finger enhance to imaging be of step of
to the important as observed a studies, that been a XeXX may Sandy gene dose when concentration efficacy above in AAVX on insights achieved. in vehicles XeXX an this where increased in we’ve the And believe the once And seen dose is vivo hemophilia And A, our intracellular this Slide suggests level. to dose the therapy AAVX clearly vehicle from thresholds we will that’s significant clinical critical be be including delivery XX. earlier, mentioned the through defined gained in that the has increases delivery SB-XXX various we our back effective setting into program
that vitro extremely sufficient is in increasing consider transduction. combined an know Now the efficiency when levels And studies for preclinical obtained. editor finger complementary in several of vivo intracellular knowledge to our we with and already AAVX largely have of this both been is further thresholds, genome methods zinc efficient understanding, from the hepatocellular
under the the concentration current to improve of of matters finger finally, AAV key zinc ratio AAVX containing follows: fingers increase adjusting generation finger editing the transduction enhanced third, efficiency; first, the albumin constructs which our of safety for deploying genome And precision, second, by species; the total on the administered updated to experience; supported are AAV, engineering zinc our with specificity. next and is efficiency dose and consideration transgene increasing to locus as donor each and zinc
time believe will new We’re options. currently end our assumptions, the of the that frame the the these manufacturing by we XXXX. to planning be and on to evaluate preclinical process in this program current studies And based AAVX, of clinic initiating in several including
will this know as when more. investors on timing we and We update
Officer, the Technology Rebar, Chief over assay. the Ed? Ed now provide I’d And and technology will our preclinical like turn to call to who
